Developing Human STING Pathway Inhibitor Assets
Transforming Inflammation Science Into Disease-Modifying Therapies
IFNRx develops novel small-molecule inhibitors of the STING signaling pathway to reduce chronic inflammation in neurodegenerative and autoimmune diseases.
Lead Program
- Three hit-to-lead candidates with favorable ADME and tissue distribution
- In-vitro STING inhibition at IC50 ≤ 1.0 µM
- Activity in human neural epithelial cells
- Efficacy in STING-driven rat and mouse models
- Oral exposure + blood-brain barrier penetration
